Hydrogen Sulfide and Peripheral Arterial Disease
This will be an observational study comparing the plasma levels of free hydrogen sulfide in patients with and without peripheral arterial disease using a novel recently published method of measuring hydrogen sulfide. The investigators will also see if there is any difference in these levels between symptomatic and asymptomatic patients. Will examine the relationship of these levels to known clinical risk factors as well as plasma nitrite and nitric oxide levels. In doing the above the investigators hope to explore the utility of free hydrogen sulfide as a biomarker for peripheral arterial disease.
Atherosclerotic peripheral arterial disease (PAD) of the lower extremities represents a significant and growing cause of morbidity and mortality. The PARTNERS study of screening ABIs in a primary care population of nearly 7000 individuals demonstrated a remarkable 29% incidence of ABI <0.9, which is the commonly accepted level of abnormal ABI diagnostic of PAD. Also of note in these patients with a new diagnosis of PAD the incidence of asymptomatic PAD was a striking 48%. The availability of a biomarker will greatly enhance the care of these patient and hopefully reduce morbidity and mortality.
The investigators believe that hydrogen sulfide (H2S), an endogenously produced gasotransmitter, holds promise as a clinically useful biomarker for PAD and may also provide a possible explanation for the paradox of asymptomatic PAD in patients with ABIs less than 0.9. To date, research regarding H2S has demonstrated that it participates in a myriad of physiological functions including vasodilatation, anti-apoptotic effects, modulation of mitochondrial respiration, and changes in vascular remodeling.
|Peripheral Arterial Disease|
|Study Design:||Observational Model: Cohort
Time Perspective: Cross-Sectional
|Official Title:||Hydrogen Sulfide and Peripheral Arterial Disease|
- Free plasma hydrogen sulfide levels [ Time Frame: day 1 at enrollment only, we will not be prospectively following these levels. ]Will be evaluating plasma free hydrogen sulfide levels in the three cohorts of patients.
- Plasma nitrite and nitric oxide levels. [ Time Frame: day 1 at enrollment only, we will not be prospectively following these levels. ]Will evaluate the plasma levels of nitrite and nitric oxide in the three cohorts of patients.
Biospecimen Retention: Samples Without DNA
|Study Start Date:||August 2011|
|Study Completion Date:||June 2012|
|Primary Completion Date:||June 2012 (Final data collection date for primary outcome measure)|
Patient with symptomatic PAD as defined by the presence of typical or atypical claudication symptoms or critical limb ischemia in conjunction with ABI <0.9.
Patients without PAD
Patients without PAD as defined by ABI>0.9 and <1.3.
Patients with asymptomatic PAD as defined by ABI<0.9 but no symptoms.
The investigators will conduct an observational cohort study to evaluate H2S levels in three groups of patients:
- Patients without PAD as defined by ABI>0.9 and <1.3.
- Patients with asymptomatic PAD as defined by ABI<0.9 but no symptoms
- Patient with symptomatic PAD as defined by the presence of typical or atypical claudication symptoms or critical limb ischemia in conjunction with ABI <0.9.
This will be a single center study performed at LSUHSC-Shreveport. Patients undergoing cardiac catheterization or peripheral angiogram via a major arterial approach at the LSUHSC cardiac catheterization laboratory meeting the inclusion and exclusion criteria will be eligible and given an opportunity to participate. Those providing informed consent will be interviewed for the presence of claudication symptoms, by use of the San Diego Claudication Questionnaire and the presence of known risk factors for PAD. The medical record will be reviewed for collection of baseline clinical data including known risk factors for vascular disease as well as medications etc. Ankle Brachial Index will be measured by the standard technique of non-invasive measurement of bilateral arm and ankle pressures and recorded in all patients.
Plasma free H2S level quantification via high performance liquid gas chromatography, as well as plasma nitrite levels and nitric oxide levels by chemiluminescence assay will be performed.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01407172
|United States, Louisiana|
|Shreveport, Louisiana, United States, 71130|
|Principal Investigator:||Christopher Kevil, PhD||LSUHSC Shreveport|